1. Economics of biological therapies;Kelly;BMJ,2009
2. Public biotech 2012—the numbers;Huggett;Nat Biotechnol,2013
3. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf [accessed 29.08.14].
4. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf [accessed 29.08.14].
5. Study to demonstrate equivalent efficacy and to compare safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS). Available from: https://clinicaltrials.gov/ct2/show/NCT02016105?term=biosimilar+adalimumab&rank=1 [accessed 29.08.14].